Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients

Nicolas Girard, Pauline Macouillard, Danalyn Byng, Jie Meng, Friso Coerts, Shannon Hunter, Alessandria Struebing, Yan Xiong, Sarah Park, M. Inaam Haq, Olga Tymejczyk, Christos Chouaid, Clarisse Audigier-Valette, Didier Debieuvre, Xavier Quantin, Lise Bosquet, Maurice Pérol

Open source

DOI: 10.1007/s12325-025-03465-4
Published: 2026-02-13
Container: Advances in Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-025-03465-4,
  title = {Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients},
  author = {Nicolas Girard and Pauline Macouillard and Danalyn Byng and Jie Meng and Friso Coerts and Shannon Hunter and Alessandria Struebing and Yan Xiong and Sarah Park and M. Inaam Haq and Olga Tymejczyk and Christos Chouaid and Clarisse Audigier-Valette and Didier Debieuvre and Xavier Quantin and Lise Bosquet and Maurice Pérol},
  year = {2026},
  journal = {Advances in Therapy},
  doi = {10.1007/s12325-025-03465-4},
  url = {https://doi.org/10.1007/s12325-025-03465-4}
}

RIS

TY  - JOUR
TI  - Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
AU  - Nicolas Girard
AU  - Pauline Macouillard
AU  - Danalyn Byng
AU  - Jie Meng
AU  - Friso Coerts
AU  - Shannon Hunter
AU  - Alessandria Struebing
AU  - Yan Xiong
AU  - Sarah Park
AU  - M. Inaam Haq
AU  - Olga Tymejczyk
AU  - Christos Chouaid
AU  - Clarisse Audigier-Valette
AU  - Didier Debieuvre
AU  - Xavier Quantin
AU  - Lise Bosquet
AU  - Maurice Pérol
PY  - 2026
JO  - Advances in Therapy
DO  - 10.1007/s12325-025-03465-4
UR  - https://doi.org/10.1007/s12325-025-03465-4
ER  -

APA

Girard, N., Macouillard, P., Byng, D., Meng, J., Coerts, F., Hunter, S., Struebing, A., Xiong, Y., Park, S., Haq, M. I., Tymejczyk, O., Chouaid, C., Audigier-Valette, C., Debieuvre, D., Quantin, X., Bosquet, L., & Pérol, M. (2026). Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients. Advances in Therapy. https://doi.org/10.1007/s12325-025-03465-4

Source records

crossref · retrieved 2026-09-26T19:58:08.913Z